Delstrigo is a complete regimen for the treatment of HIV-1 infection; therefore, Delstrigo should not be administered with other antiretroviral medicinal products. Doravirine/lamivudine/tenofovir disoproxil must not be co-administered with medicinal products containing tenofovir disoproxil. Coadministration of tenofovir disoproxil (300 mg once daily) and doravirine (100 mg single dose) decreased doravirine AUC, Cmax and C24 by 5%, 20% and 6%, respectively.

Because Delstrigo is a complete regimen for the treatment of HIV-1 infection, co-administration with other antiretroviral medications for treatment of HIV-1 infection is not recommended. No clinically significant change in drug concentrations were observed when tenofovir was co-administered with doravirine.

Co-administration of doravirine (100 mg single dose) with tenofovir-DF (300 mg once daily) was studied in 8 healthy male subjects. Doravirine AUC, Cmax and C24 decreased by 3%, 18% and 5%, respectively. The authors conclude that tenofovir-DF does not have not have a clinically relevant impact on doravirine pharmacokinetics.